A total of 20 FMGs were also defined in ICC samples from the MSK cohort, including IDH1 (22%), ARID1A (21%), BAP1 (19%), TP53 (18%), PBRM1 (11%), KRAS (10%), BRAF (7%), ATM (5%), FGFR2 (5%), and IDH2 (5%) (Figure 1B). This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.